Radiation Therapy or Standard Therapy in Treating Women With Stage II Breast Cancer Who Have Undergone Mastectomy
The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2009 by National Cancer Institute (NCI).
Recruitment status was Recruiting
Recruitment status was Recruiting
Sponsor:
Medical Research Council
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00966888
First received: August 26, 2009
Last updated: September 29, 2009
Last verified: August 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Radiation therapy uses high-energy x-rays or other types of radiation to kill tumor cells. Giving radiation therapy after surgery may kill any tumor cells that remain after surgery. It is not yet known whether radiation therapy is more effective than observation after mastectomy in treating women with stage II breast cancer.
PURPOSE: This randomized phase III trial is studying radiation therapy to see how well it works compared with standard therapy in treating women with stage II breast cancer who have undergone mastectomy.
| Condition | Intervention | Phase |
|---|---|---|
|
Breast Cancer |
Procedure: standard follow-up care Radiation: radiation therapy |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Primary Purpose: Treatment |
| Official Title: | Selective Use of Postoperative Radiotherapy AftEr MastectOmy - SUPREMO |
Resource links provided by NLM:
Further study details as provided by National Cancer Institute (NCI):
Primary Outcome Measures:
- Overall survival [ Designated as safety issue: No ]
- Acute and late morbidity [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Chest wall recurrence [ Designated as safety issue: No ]
- Regional recurrence [ Designated as safety issue: No ]
- Disease-free survival [ Designated as safety issue: No ]
- Metastasis-free survival [ Designated as safety issue: No ]
- Cause of death (breast cancer, or intercurrent disease [cardiovascular or non-cardiovascular]) [ Designated as safety issue: No ]
- Quality of life [ Designated as safety issue: No ]
- Cost effectiveness [ Designated as safety issue: No ]
| Estimated Enrollment: | 3500 |
| Study Start Date: | January 2006 |
| Estimated Primary Completion Date: | June 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Arm I
Beginning 12 weeks after mastectomy or 6 weeks after adjuvant chemotherapy, patients undergo radiotherapy 5 days a week for 3-5 weeks in the absence of disease progression or unacceptable toxicity.
|
Radiation: radiation therapy
Chest wall radiotherapy
|
|
Active Comparator: Arm II
Patients receive standard of care and observation only.
|
Procedure: standard follow-up care
No intervention
|
Detailed Description:
OBJECTIVES:
- Determine the overall survival of women at intermediate risk for locoregional recurrence of breast cancer treated with ipsilateral chest wall adjuvant radiotherapy after mastectomy.
OUTLINE: This is a multicenter study. Patients are randomized to 1 of 2 treatment arms.
- Arm I: Beginning 12 weeks after mastectomy or 6 weeks after adjuvant chemotherapy, patients undergo radiotherapy 5 days a week for 3-5 weeks in the absence of disease progression or unacceptable toxicity.
- Arm II: Patients receive standard of care and observation only. After completion of study therapy, patients are followed up twice in the first year, and then annually for up to 10 years.
Eligibility| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Criteria
DISEASE CHARACTERISTICS:
Histologically confirmed unilateral invasive breast cancer
- pT1, pN1, M0 disease
- pT2, pN1, M0 disease
- pT2, pN0 disease with grade III histology and/or lymphovascular invasion
Multifocal breast cancer meeting both of the following criteria:
- Largest discrete tumor ≥ 2 cm if N0
- Grade III histology and/or lymphovascular invasion
- No bilateral breast cancer
Axillary node negative status by axillary clearance, axillary node sampling, or sentinel node biopsy
Patients with axillary node positive (1-3 positive nodes, including micrometastases* > 0.2 mm and ≤ 2 mm) must have had an axillary node clearance (minimum of 10 nodes removed) performed
- No more than 3 pathologically involved lymph nodes
- No internal mammary nodes visible on sentinel node scintigraphy in the absence of negative histology NOTE: *Isolated tumor cells not counted as micrometastases
Underwent total mastectomy (with minimum of 1 mm margin clear of invasive cancer and DCIS) and axillary surgery with staging procedure
- Must have undergone adjuvant systemic chemotherapy if indicated for intermediate-risk breast cancer
- Patients undergoing immediate breast reconstruction allowed
- No known BRCA1 and BRCA2 carriers
- Hormone receptor status not specified
PATIENT CHARACTERISTICS:
- Menopausal status not specified
- Not pregnant
- Fit for adjuvant chemotherapy, adjuvant endocrine therapy, and post-operative radiotherapy
- No prior or concurrent malignancy except curatively treated nonmelanomatous skin cancer or carcinoma in situ of the cervix
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- No concurrent trastuzumab
- No prior neoadjuvant systemic therapy
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00966888
Locations
| United Kingdom | |
| Edinburgh Cancer Centre at Western General Hospital | Recruiting |
| Edinburgh, Scotland, United Kingdom, EH4 2XU | |
| Contact: Ian H. Kunkler, MD 44-131-537-2214 i.kunkler@ed.ac.uk | |
| Royal Infirmary - Castle | Recruiting |
| Glasgow, Scotland, United Kingdom, G4 0SF | |
| Contact: Peter A. Canney, MD 44-141-211-1160 | |
Sponsors and Collaborators
Medical Research Council
Investigators
| Principal Investigator: | Ian H. Kunkler, MD | Edinburgh Cancer Centre at Western General Hospital |
More Information
Additional Information:
No publications provided
| ClinicalTrials.gov Identifier: | NCT00966888 History of Changes |
| Other Study ID Numbers: | CDR0000642751, MRC-BIG2-04, ISRCTN-61145589, EU-20943 |
| Study First Received: | August 26, 2009 |
| Last Updated: | September 29, 2009 |
| Health Authority: | Unspecified |
Keywords provided by National Cancer Institute (NCI):
|
stage II breast cancer |
Additional relevant MeSH terms:
|
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases |
ClinicalTrials.gov processed this record on May 22, 2013